| Safety, Tolerability, and Immunogenicity of GS-4774,an HBV-Specific Therapeutic Vaccine, in Healthy Volunteers
| | | Reported by Jules Levin
AASLD Nov 1-4 2013 Wash DC
Anuj Gaggar,1 Claire Coeshott,2 David Apelian,2 Tim Rodell,2 Gong Shen,1 Mani Subramanian,1 John McHutchison1
1Gilead Sciences, Inc., Foster City, CA; 2GlobeImmune, Louisville, CO
| |
| |